Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GABRA2 | P47869 | 12/20 | 0.43 |
| ▸ | GABRB2 | P47870 | 12/20 | 0.43 |
| ▸ | HCAR1 | Q9BXC0 | 1/20 | 0.39 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.39 |
| ▸ | OPRL1 | P41146 | 1/20 | 0.37 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.36 |
| ▸ | S1PR4 | O95977 | 1/20 | 0.36 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27564981 | 0.70 | GABRA2 (0.48) | GABRA2GABRB2HCAR1OPRL1L3MBTL1 | |
| SCHEMBL24257824 | 0.66 | NOTUM (0.45) | GABRA2GABRB2NOTUML3MBTL1 | |
| SCHEMBL14996548 | 0.64 | LMNA (0.48) | OPRL1L3MBTL1 | |
| SCHEMBL28816238 | 0.63 | NOTUM (0.47) | GABRA2GABRB2NOTUML3MBTL1 | |
| SCHEMBL8047156 | 0.62 | HCAR1 (0.42) | GABRA2GABRB2HCAR1NOTUML3MBTL1 | |
| SCHEMBL12859450 | 0.61 | LMNA (0.42) | L3MBTL1 | |
| SCHEMBL3298524 | 0.61 | KDM4E (0.46) | GABRA2GABRB2HCAR1NOTUMCYP11B2 | |
| SCHEMBL30055522 | 0.61 | NOTUM (0.56) | HCAR1NOTUML3MBTL1 | |
| SCHEMBL28215980 | 0.61 | NOTUM (0.43) | GABRA2GABRB2HCAR1NOTUML3MBTL1 | |
| SCHEMBL11023550 | 0.61 | NOTUM (0.56) | HCAR1NOTUML3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2793894-A1 | HETEROARYLS AND USES THEREOF | Millennium Pharmaceuticals, Inc. (US) | 2014-10-29 | — | — | EP | disclosed |
| WO-2013096642-A1 | HETEROARYLS AND USES THEREOF | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2013-06-27 | — | — | WO | disclosed |
| WO-2013096642-A1 | HETEROARYLS AND USES THEREOF | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2013-06-27 | — | — | WO | disclosed |
| US-20130165472-A1 | HETEROARYLS AND USES THEREOF | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2013-06-27 | — | — | US | disclosed |
| US-20130165472-A1 | HETEROARYLS AND USES THEREOF | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2013-06-27 | — | — | US | disclosed |
| US-20130165472-A1 | HETEROARYLS AND USES THEREOF | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2013-06-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130165472-A1 | HETEROARYLS AND USES THEREOF | PIK3R4, VPS4B, PIK3C2A | GABRA2 3457/4885GABRB2 2982/4885HCAR1 288/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.